Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada.
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada; Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, Canada.
Ophthalmol Retina. 2020 May;4(5):461-470. doi: 10.1016/j.oret.2020.01.024. Epub 2020 Feb 13.
The role of topical nonsteroidal anti-inflammatory drugs (NSAIDs) for the reduction of ocular pain after intravitreal injections (IVIs) has been explored. To provide clarity on the evidence for these agents, the present meta-analysis of randomized controlled trials (RCTs) was undertaken.
No standard of care regimen exists for the management of pain resulting from IVIs.
A systematic literature search was conducted on Ovid MEDLINE, EMBASE, and Cochrane Central from inception through July 2019. The RCTs that treated patients with a topical NSAID and assessed postprocedural pain were included. Risk of bias was assessed using the Cochrane guidelines. For all analyses, weighted mean differences (WMDs) with 95% confidence intervals (CIs) were reported. Random effects models were used for all analyses. The primary analysis analyzed pain on a 0- to 10-point visual analog scale. Literature estimates were categorized into the following postprocedure time point groups: 1 hour or less, 1 to 24 hours (although data were available only at 6 hours), and 24 hours or more. A subgroup analysis stratified studies based on agent and preprocedure versus postprocedure administration.
From 241 results, 9 RCTs and 598 eyes were included. A low to medium risk of bias was found across the included studies. The mean pain score on a 0-to-10 visual analog scale was significantly lower after topical NSAID administration relative to control at 1 hour or less after IVI (WMD, -1.01 units; 95% CI, -1.38 to -0.65; P < 0.001), 6 hours after IVI (WMD, -2.17 units; 95% CI, -2.67 to -1.68; P < 0.001; threshold met for clinical significance, defined as WMD >1.2 units), and more than 24 hours after IVI (WMD, -0.75 units; 95% CI, -1.11 to -0.38; P < 0.001). A greater effect size was seen with administration of NSAIDs before versus after IVI, as well as topical nepafenac relative to ketorolac or diclofenac.
At 6 hours after the procedure, NSAIDs provide a clinically meaningful reduction in pain relative to a control group. The administration of NSAIDs before the procedure, specifically topical nepafenac, was associated with the greatest improvement in pain relative to the control group.
局部非甾体抗炎药(NSAIDs)在减少玻璃体腔注射(IVI)后眼部疼痛中的作用已被探讨。为了阐明这些药物的证据,本随机对照试验(RCT)的荟萃分析进行了。
目前尚无治疗 IVI 引起的疼痛的标准治疗方案。
对 Ovid MEDLINE、EMBASE 和 Cochrane 中央从开始到 2019 年 7 月进行了系统的文献检索。纳入了用局部 NSAID 治疗并评估术后疼痛的 RCT。使用 Cochrane 指南评估偏倚风险。对于所有分析,报告加权均数差异(WMD)及其 95%置信区间(CI)。所有分析均使用随机效应模型。主要分析分析了 0-10 分视觉模拟量表上的疼痛。文献估计分为以下术后时间点组:1 小时或更短,1-24 小时(尽管仅在 6 小时时有数据),24 小时或更长。基于药物和术前与术后给药,对研究进行了亚组分析。
从 241 项结果中,纳入了 9 项 RCT 和 598 只眼。纳入的研究存在低到中度偏倚风险。与对照组相比,在 IVI 后 1 小时或更短时间(WMD,-1.01 单位;95%CI,-1.38 至-0.65;P < 0.001)、IVI 后 6 小时(WMD,-2.17 单位;95%CI,-2.67 至-1.68;P < 0.001;定义为 WMD >1.2 单位的临床意义阈值)和 IVI 后 24 小时或更长时间(WMD,-0.75 单位;95%CI,-1.11 至-0.38;P < 0.001),局部 NSAID 给药后疼痛评分显著降低。与 IVI 后给药相比,IVI 前给药(如,局部奈帕芬那)以及与酮咯酸或双氯芬酸相比,NSAIDs 给药与对照组相比,疼痛改善程度更大。
在术后 6 小时,与对照组相比,NSAIDs 可显著减轻疼痛。与对照组相比,在手术前给予 NSAIDs,特别是局部奈帕芬那,与疼痛的最大改善相关。